Phase II trial to evaluate immune-related biomarkers for pathological response in stage II-III HER2-positive breast cancer receiving neoadjuvant chemotherapy with subsequent randomization to multi-epitope HER2 vaccine versus placebo in patients with residual disease post-neoadjuvant chemotherapy.
JOURNAL OF CLINICAL ONCOLOGY（2022）
关键词
breast cancer,vaccine,immune-related,ii-iii,multi-epitope,post-neoadjuvant
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要